Screening of Antiviral Activity of Naturally Occurring Substances Against Herpes Simplex Virus

Background. Herpesviruses are among the most common human pathogens that cause a variety of diseases, including herpetic stomatitis, ophthalmic herpes, genital herpes, chickenpox, and shingles. Despite the availability of several effective medicines, such as acyclovir and valacyclovir, there is a need for the development of new medications with increased efficacy, reduced toxicity, and the ability to overcome viral resistance.

The aim of the study was to identify and evaluate the antiviral activity of naturally occurring compounds against the herpes simplex virus in vitro.

Results. Echinacea and hawkweed extracts demonstrated the most pronounced antiviral protection against the herpes simplex virus. Among pure chemical compounds, caffeic acid was found to be the most active against herpes simplex virus type 2.

Conclusion. The obtained data demonstrate the potential of plant compounds for the development of new treatments for herpes infections. Among the compounds studied, echinacea and hawkweed extracts are the most promising and can be considered as candidates for the development of natural antiherpetic medications. 

1. Godfrey HR, Godfley NJ, Godfley JC, Riley D. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med. 2001; 3 (7): 49–56.

2. Infekcionny`e bolezni u detej. Pod redakciej professora VN Timchenko. 4-e izdanie. Sankt-Peterburg: SpeczLit, 2012; 623. ISBN 978-5-299-00493-9. EDN SUESZJ. (in Russ.)].

3. Sorokin YuN. Gerpeticheskie porazheniya perifericheskoj nervnoj sistemy`. Lekciya (pervoe soobshhenie) obshhee predstavlenie i klinicheskie proyavleniya. Mezhdunarodny`j nevrologicheskij zhurnal. 2015; 1 (71): 148–153. (in Russ.)]. https://cyberleninka.ru/article/n/gerpeticheskie-porazheniya-perifericheskoynervnoy-sistemy-lektsiya-pervoe-soobschenie-obschee-predstavlenie-iklinicheskie

4. World Health Organization. (11.12.2024). «Herpes simplex virus». https://www.who.int/news-room/fact-sheets/detail/herpes-simplexvirus

5. Markelova EV, Knysh SV, Nevezhkina TA, Baibarina EV. Alphaherpesviruses: the modern look at the viral structure. Pacific Medical Journal. 2018; 4: 5–9. (in Russ.)].

6. Mardanly SG, Arseneva VA, Mardanly SS, Rotanov SV. The prevalence rate of human herpes viruses among different age populayions. 2019; 2: 50–55. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii. (in Russ.)]. https://cyberleninka.ru/article/n/rasprostranennost-virusov-gerpesa-cheloveka-sredi-kontingentov-razlichnogovozrasta

7. Mandal P, Pujol CAP, Damonte EB, Ghosh T, Ray B. Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity. Int J Biol Macromol. 2010; 2 (46): 173–178. doi: 10.1016/j.ijbiomac.2009.12.003.

8. Korovina AN, Kuhanova MK, Kochetkov SN. Search of inhibitors of herpes viral replication: 30 years after acyclovir. Biotechnol. acta. 2013; 4: 78–85. (in Russ.)]. URL: https://cyberleninka.ru/article/n/poiskingibitorov-replikatsii-virusa-gerpesa-30-let-posle-atsiklovira (дата обращения: 02.10.2025).

9. Richard W, Joel B. Clinical management of herpes simplex virus infections: past, present, and future. F1000Res. 2018;7: F1000 Faculty Rev-1726. doi: 10.12688/f1000research.16157.1.

10. Levina AS, Babachenko IV, Skripchenko NV, Chebotareva TA, Gemina OI. Therapy of chronic herpesvirus infection in frequently ill children. Possible causes of inefficiency. Russian Journal of Woman and Child Health. 2022; 5 (4): 332–339 (in Russ.). doi: https://doi.org/10.32364/2618-8430-2022-5-4-332-339.

11. Field HJ. Persistent herpes simplex virus infection and mechanisms of virus drug resistance. Eur J Clin Microbiol Infect Dis. 1989; 8: 671–680. doi: 10.1007/BF01963751.

12. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011; 55: 459–72. doi: 10.1128/AAC.00615-10.

13. Reed J, Muench H. A simple method of estimating fifty percent endpoints. American Journal of Epidemiology. 1938; 27: 493–497.

14. Sivak KV, Stosman KI, Lesiovskaya EE. Bioactive compounds of medicinal plants with anti-herpes effect (part 1). Vegetation Resources. 2024; 60 (2): 3–20. (in Russ.)]. doi: https://doi.org/10.31857/S0033994624020017.

15. Sivak КV, Stosman KI, Lesiovskaya EE, Savateeva-Lubimova TN, Fedorova VA. Bioactive compounds of medicinal plants with anti-herpetic effect (part 2). Vegetation Resources. 2025; 61 (2): 40–55. (in Russ.)]. doi: https://doi.org/10.31857/S0033994625020037.

16. Birkmann A, Saunders R. Overview on the management of herpes simplex virus infections: Current therapies and future directions. Antiviral Res. 2025; 237: 106152. doi: 10.1016/j.antiviral.2025.106152.

17. James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020; 98 (5): 315–329. doi: 10.2471/BLT.19.237149.

18. Thompson KD. Antiviral activity of Viracea® against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus. Antivir Res. 1998; 39 (1): 55–61. doi: 10.1016/S0166-3542(98)00027-8.

19. Min BS, Bae KH, Kim YH, Miyashiro H, Hattori M, Shimotohno K. Screening of Korean plants against human immunodeficiency virus type 1 protease. Phytother Res. 1999; 13 (8): 680–682. doi: 10.1002/(sici)10991573(199912)13:8<680: aid-ptr501>3.0.co;2-h.